Cargando…

Enhancing the Anti-Leukemic Potential of Thymoquinone/Sulfobutylether-β-cyclodextrin (SBE-β-CD) Inclusion Complexes

Leukemia, a condition characterized by the abnormal proliferation of blood cells, poses significant challenges in cancer treatment. Thymoquinone (TQ), a bioactive compound derived from black seed, has demonstrated anticancer properties, including telomerase inhibition and the induction of apoptosis....

Descripción completa

Detalles Bibliográficos
Autores principales: Eid, Eltayeb E. M., Alshehade, Salah Abdalrazak, Almaiman, Amer A., Kamran, Sareh, Lee, Vannajan Sanghiran, Alshawsh, Mohammed Abdullah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377214/
https://www.ncbi.nlm.nih.gov/pubmed/37509531
http://dx.doi.org/10.3390/biomedicines11071891
_version_ 1785079462531956736
author Eid, Eltayeb E. M.
Alshehade, Salah Abdalrazak
Almaiman, Amer A.
Kamran, Sareh
Lee, Vannajan Sanghiran
Alshawsh, Mohammed Abdullah
author_facet Eid, Eltayeb E. M.
Alshehade, Salah Abdalrazak
Almaiman, Amer A.
Kamran, Sareh
Lee, Vannajan Sanghiran
Alshawsh, Mohammed Abdullah
author_sort Eid, Eltayeb E. M.
collection PubMed
description Leukemia, a condition characterized by the abnormal proliferation of blood cells, poses significant challenges in cancer treatment. Thymoquinone (TQ), a bioactive compound derived from black seed, has demonstrated anticancer properties, including telomerase inhibition and the induction of apoptosis. However, TQ’s poor solubility and limited bioavailability hinder its clinical application. This study explored the use of Sulfobutylether-β-cyclodextrin (SBE-β-CD), a cyclodextrin derivative, to enhance the solubility and stability of TQ for leukemia treatment. SBE-β-CD offers low hemolytic activity and has been successfully employed in controlled drug release systems. The study investigated the formation of inclusion complexes between TQ and SBE-β-CD and evaluated their effects on leukemia cell growth and telomerase activity. The results indicated that the TQ/SBE-β-CD complex exhibited improved solubility and enhanced cytotoxic effects against K-562 leukemia cells compared to TQ alone, suggesting the potential of SBE-β-CD as a drug delivery system for TQ. The annexin V-FITC assay demonstrated increased apoptosis, while the qPCR quantification assay revealed reduced telomerase activity in leukemia cells treated with TQ/SBE-β-CD, supporting its anti-leukemic potential. The molecular docking analysis indicated a strong binding affinity between TQ and telomerase. However, further research is needed to optimize the apoptotic effects and minimize necrosis induction. In conclusion, TQ/SBE-β-CD shows promise as a novel strategy for leukemia treatment by inhibiting telomerase and enhancing the cytotoxic effects of TQ, offering a potential solution to overcome the limitations of TQ’s poor solubility and bioavailability.
format Online
Article
Text
id pubmed-10377214
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103772142023-07-29 Enhancing the Anti-Leukemic Potential of Thymoquinone/Sulfobutylether-β-cyclodextrin (SBE-β-CD) Inclusion Complexes Eid, Eltayeb E. M. Alshehade, Salah Abdalrazak Almaiman, Amer A. Kamran, Sareh Lee, Vannajan Sanghiran Alshawsh, Mohammed Abdullah Biomedicines Article Leukemia, a condition characterized by the abnormal proliferation of blood cells, poses significant challenges in cancer treatment. Thymoquinone (TQ), a bioactive compound derived from black seed, has demonstrated anticancer properties, including telomerase inhibition and the induction of apoptosis. However, TQ’s poor solubility and limited bioavailability hinder its clinical application. This study explored the use of Sulfobutylether-β-cyclodextrin (SBE-β-CD), a cyclodextrin derivative, to enhance the solubility and stability of TQ for leukemia treatment. SBE-β-CD offers low hemolytic activity and has been successfully employed in controlled drug release systems. The study investigated the formation of inclusion complexes between TQ and SBE-β-CD and evaluated their effects on leukemia cell growth and telomerase activity. The results indicated that the TQ/SBE-β-CD complex exhibited improved solubility and enhanced cytotoxic effects against K-562 leukemia cells compared to TQ alone, suggesting the potential of SBE-β-CD as a drug delivery system for TQ. The annexin V-FITC assay demonstrated increased apoptosis, while the qPCR quantification assay revealed reduced telomerase activity in leukemia cells treated with TQ/SBE-β-CD, supporting its anti-leukemic potential. The molecular docking analysis indicated a strong binding affinity between TQ and telomerase. However, further research is needed to optimize the apoptotic effects and minimize necrosis induction. In conclusion, TQ/SBE-β-CD shows promise as a novel strategy for leukemia treatment by inhibiting telomerase and enhancing the cytotoxic effects of TQ, offering a potential solution to overcome the limitations of TQ’s poor solubility and bioavailability. MDPI 2023-07-04 /pmc/articles/PMC10377214/ /pubmed/37509531 http://dx.doi.org/10.3390/biomedicines11071891 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Eid, Eltayeb E. M.
Alshehade, Salah Abdalrazak
Almaiman, Amer A.
Kamran, Sareh
Lee, Vannajan Sanghiran
Alshawsh, Mohammed Abdullah
Enhancing the Anti-Leukemic Potential of Thymoquinone/Sulfobutylether-β-cyclodextrin (SBE-β-CD) Inclusion Complexes
title Enhancing the Anti-Leukemic Potential of Thymoquinone/Sulfobutylether-β-cyclodextrin (SBE-β-CD) Inclusion Complexes
title_full Enhancing the Anti-Leukemic Potential of Thymoquinone/Sulfobutylether-β-cyclodextrin (SBE-β-CD) Inclusion Complexes
title_fullStr Enhancing the Anti-Leukemic Potential of Thymoquinone/Sulfobutylether-β-cyclodextrin (SBE-β-CD) Inclusion Complexes
title_full_unstemmed Enhancing the Anti-Leukemic Potential of Thymoquinone/Sulfobutylether-β-cyclodextrin (SBE-β-CD) Inclusion Complexes
title_short Enhancing the Anti-Leukemic Potential of Thymoquinone/Sulfobutylether-β-cyclodextrin (SBE-β-CD) Inclusion Complexes
title_sort enhancing the anti-leukemic potential of thymoquinone/sulfobutylether-β-cyclodextrin (sbe-β-cd) inclusion complexes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377214/
https://www.ncbi.nlm.nih.gov/pubmed/37509531
http://dx.doi.org/10.3390/biomedicines11071891
work_keys_str_mv AT eideltayebem enhancingtheantileukemicpotentialofthymoquinonesulfobutyletherbcyclodextrinsbebcdinclusioncomplexes
AT alshehadesalahabdalrazak enhancingtheantileukemicpotentialofthymoquinonesulfobutyletherbcyclodextrinsbebcdinclusioncomplexes
AT almaimanamera enhancingtheantileukemicpotentialofthymoquinonesulfobutyletherbcyclodextrinsbebcdinclusioncomplexes
AT kamransareh enhancingtheantileukemicpotentialofthymoquinonesulfobutyletherbcyclodextrinsbebcdinclusioncomplexes
AT leevannajansanghiran enhancingtheantileukemicpotentialofthymoquinonesulfobutyletherbcyclodextrinsbebcdinclusioncomplexes
AT alshawshmohammedabdullah enhancingtheantileukemicpotentialofthymoquinonesulfobutyletherbcyclodextrinsbebcdinclusioncomplexes